AssetMark Inc’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.31M | Buy |
49,713
+5,741
| +13% | +$276K | ﹤0.01% | 917 |
|
|
2026
Q1 | $2.27M | Buy |
43,972
+2,578
| +6% | +$131K | ﹤0.01% | 858 |
|
|
2025
Q4 | $2.06M | Buy |
41,394
+1,670
| +4% | +$81.2K | ﹤0.01% | 846 |
|
|
2025
Q3 | $1.9M | Buy |
39,724
+3,020
| +8% | +$122K | ﹤0.01% | 823 |
|
|
2025
Q2 | $1.16M | Sell |
36,704
-1,259
| -3% | -$40.3K | ﹤0.01% | 894 |
|
|
2025
Q1 | $1.24M | Buy |
37,963
+4,748
| +14% | +$168K | ﹤0.01% | 827 |
|
|
2024
Q4 | $1.2M | Sell |
33,215
-227
| -0.7% | -$7.99K | ﹤0.01% | 811 |
|
|
2024
Q3 | $1.04M | Buy |
33,442
+908
| +3% | +$28.3K | ﹤0.01% | 773 |
|
|
2024
Q2 | $870K | Buy |
32,534
+1,432
| +5% | +$41.5K | ﹤0.01% | 798 |
|
|
2024
Q1 | $1.06M | Buy |
31,102
+1,403
| +5% | +$41.8K | ﹤0.01% | 718 |
|
|
2023
Q4 | $859K | Buy |
29,699
+1,121
| +4% | +$29.7K | ﹤0.01% | 710 |
|
|
2023
Q3 | $788K | Buy |
28,578
+629
| +2% | +$19.1K | ﹤0.01% | 660 |
|
|
2023
Q2 | $840K | Buy |
27,949
+1,956
| +8% | +$68.4K | ﹤0.01% | 642 |
|
|
2023
Q1 | $942K | Buy |
25,993
+1,423
| +6% | +$54.7K | ﹤0.01% | 611 |
|
|
2022
Q4 | $876K | Buy |
24,570
+558
| +2% | +$19.4K | ﹤0.01% | 604 |
|
|
2022
Q3 | $813K | Buy |
24,012
+22,107
| +1,160% | +$719K | ﹤0.01% | 560 |
|
|
2022
Q2 | $55K | Buy |
1,905
+283
| +17% | +$8.11K | ﹤0.01% | 897 |
|
|
2022
Q1 | $52K | Sell |
1,622
-15
| -0.9% | -$460 | ﹤0.01% | 912 |
|
|
2021
Q4 | $48K | Buy |
1,637
+53
| +3% | +$1.61K | ﹤0.01% | 920 |
|
|
2021
Q3 | $42K | Buy |
1,584
+15
| +1% | +$403 | ﹤0.01% | 816 |
|
|
2021
Q2 | $48K | Sell |
1,569
-3
| -0.2% | -$92 | ﹤0.01% | 759 |
|
|
2021
Q1 | $41K | Buy |
1,572
+81
| +5% | +$2.27K | ﹤0.01% | 757 |
|
|
2020
Q4 | $38K | Buy |
1,491
+161
| +12% | +$3.46K | ﹤0.01% | 756 |
|
|
2020
Q3 | $28K | Buy |
1,330
+420
| +46% | +$9.53K | ﹤0.01% | 773 |
|
|
2020
Q2 | $22K | Buy |
910
+846
| +1,322% | +$18.7K | ﹤0.01% | 784 |
|
|
2020
Q1 | $1K | Sell |
64
-22
| -26% | -$462 | ﹤0.01% | 1298 |
|
|
2019
Q4 | $2K | Buy |
86
+8
| +10% | +$194 | ﹤0.01% | 1259 |
|
|
2019
Q3 | $2K | Buy |
+78
| New | +$2.31K | ﹤0.01% | 1185 |
|
|
2018
Q1 | – | Sell |
-17
| Closed | -$1K | – | 1949 |
|
|
2017
Q4 | $1K | Buy |
+17
| New | +$672 | ﹤0.01% | 1712 |
|
Other funds holding SUPN
AC
NAMI
SIMG
AssetMark Inc's SUPN Position: Q2 2026 in Review
AssetMark Inc increased its Supernus Pharmaceuticals (SUPN) stake by 13% in Q2 2026, buying an estimated $276K and bringing the position to 49,713 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #917.
AssetMark Inc first reported a position in SUPN in Q4 2017 and has held it in 29 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- AssetMark Inc held 49,713 shares of Supernus Pharmaceuticals worth $2.31M as of Q2 2026.
- AssetMark Inc bought 5,741 Supernus Pharmaceuticals shares in Q2 2026, an estimated $276K.
- Supernus Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #917 holding.
- AssetMark Inc first reported a position in Supernus Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
- 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.